NEONC TECHNOLOGIES HOLDINGS, INC. Research and Development Expense
NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) reported Research and Development Expense of $2.65 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-10
- NEONC TECHNOLOGIES HOLDINGS, INC. research and development expense for the quarter ending 2026-06-30 was $2.65M, a 291.19% increase year-over-year.
- NEONC TECHNOLOGIES HOLDINGS, INC. research and development expense for the quarter ending 2026-03-31 was $1.29M, a 28.86% increase year-over-year.
- NEONC TECHNOLOGIES HOLDINGS, INC. research and development expense for the quarter ending 2025-12-31 was $1.25M, a 15.58% increase year-over-year.
- NEONC TECHNOLOGIES HOLDINGS, INC. research and development expense for the quarter ending 2025-09-30 was $715.04K, a 25.26% decline year-over-year.
- NEONC TECHNOLOGIES HOLDINGS, INC. research and development expense for fiscal 2025 was $3.64M, a 19.47% increase from fiscal 2024.
- NEONC TECHNOLOGIES HOLDINGS, INC. research and development expense for fiscal 2024 was $3.05M.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 6 month as first filed | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $2.65M 10-Q · filed 2026-08-10 | $3.94M 10-Q · filed 2026-08-10 | $5.18M derived: sum of 3 quarters · filed 2026-08-10 | $5.90M derived: sum of 4 quarters · filed 2026-08-10 | |
| 2026-03-31 | $1.29M 10-Q · filed 2026-05-15 | $2.53M derived: sum of 2 quarters · filed 2026-05-15 | $3.25M derived: sum of 3 quarters · filed 2026-05-15 | $3.93M derived: sum of 4 quarters · filed 2026-08-10 | |
| 2025-12-31 | $1.25M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $1.96M derived: sum of 2 quarters · filed 2026-03-31 | $2.64M derived: sum of 3 quarters · filed 2026-08-10 | $3.64M 10-K · filed 2026-03-31 | |
| 2025-09-30 | $715.04K 10-Q · filed 2025-11-14 | $1.39M derived: sum of 2 quarters · filed 2026-08-10 | $2.39M 10-Q · filed 2025-11-14 | $3.47M derived: sum of 4 quarters · filed 2026-08-10 | |
| 2025-06-30 | $677.33K 10-Q · filed 2026-08-10 | $1.64M 10-Q · filed 2026-08-10 | $1.68M 10-Q · filed 2025-08-18 | $2.76M derived: sum of 3 quarters · filed 2026-08-10 | $3.71M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | $998.22K 10-Q · filed 2026-05-15 | $2.08M derived: sum of 2 quarters · filed 2026-05-15 | $3.03M derived: sum of 3 quarters · filed 2026-05-15 | $3.43M derived: sum of 4 quarters · filed 2026-05-15 | |
| 2024-12-31 | $1.08M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $2.04M derived: sum of 2 quarters · filed 2026-03-31 | $2.43M derived: sum of 3 quarters · filed 2026-03-31 | $3.05M 10-K · filed 2026-03-31 | |
| 2024-09-30 | $956.73K 10-Q · filed 2025-11-14 | $1.35M derived: sum of 2 quarters · filed 2025-11-14 | $1.97M 10-Q · filed 2025-11-14 | ||
| 2024-06-30 | $394.48K 10-Q · filed 2025-08-18 | $1.01M 10-Q · filed 2025-08-18 | |||
| 2024-03-31 | $614.52K 10-Q · filed 2025-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| Lexaria Bioscience Corp. (LEXX) | $0.084B | -1.92 | |
| Telomir Pharmaceuticals, Inc. (TELO) | United States | $0.084B | |
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |